810509--3/31/2008--NEOPROBE

related topics

{product, candidate, development}

{product, liability, claim}

{stock, price, share}

{debt, indebtedness, cash}

{stock, price, operating}

Our products and product candidates may not achieve the broad market acceptance they need in order to be a commercial success. Clinical trials for our radiopharmaceutical product candidates will be lengthy and expensive and their outcome is uncertain. We rely on third parties for the worldwide marketing and distribution of our gamma detection and blood flow measurement devices, who may not be successful in selling our products. Our radiopharmaceutical product candidates will remain subject to ongoing regulatory review even if they receive marketing approval. If we fail to comply with continuing regulations, we could lose these approvals and the sale of our products could be suspended. We may be unable to establish the pharmaceutical manufacturing capabilities necessary to develop and commercialize our potential products. The sale of our common stock to Fusion may cause dilution and the sale of common stock acquired by Fusion could cause the price of our common stock to decline. Our products may be displaced by newer technology. The government grants Cardiosonix has received for research and development expenditures restrict our ability to manufacture blood flow monitoring products and transfer technologies outside of Israel and require us to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received together with interest and penalties, and may be subject to criminal charges. Our secured indebtedness imposes significant restrictions on us, and a default could cause us to cease operations. The price of our common stock has been highly volatile due to several factors that will continue to affect the price of our stock.

Full 10-K form ▸

810509--3/31/2008--NEOPROBE_CORP